February 24, 2017
Novartis makes first step in making Tafinlar + Mekinist available for certain NSCLC patients
Novartis could get first targeted treatment for patients with BRAF non-small cell lung cancer if European Medicines Agency (EMA) approves Tafinlar+Mikinist combination.